title: A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma.
abstract: BACKGROUND
  This trial studied the feasibility and efficacy of a new preparatory regimen for autologous bone marrow transplantation for patients with advanced lymphoid malignancies.
  
  
  METHODS
  Twenty-one patients with Hodgkin's disease (n = 12) and non-Hodgkin's lymphoma (n = 9) were treated in this study. Lomustine was substituted for carmustine) in a dose-escalation study with an initial dose of 6 mg/kg and increasing by 3 mg/kg in groups of four patients. The preparatory regimen consisted of lomustine (6-15 mg/kg) orally on Day -6, etoposide (60 mg/kg) intravenously (i.v.) on Day -4, and cyclophosphamide (100 mg/kg) i.v. on Day -2. Peripheral blood progenitor cells and/or bone marrow were infused on Day 0.
  
  
  RESULTS
  Lomustine was well tolerated in all patients with no significant toxicity specific to this drug. Engraftment was prompt: the time to achieving greater than or equal to 500 granulocytes/microliters was 12 days (range, 9-16 days) and the time to achieving greater than or equal to 25,000 platelets/microliters without transfusion support was 16 days (range, 9-22 days). Five patients experienced interstitial pneumonitis, three of whom had active or recent interstitial pneumonitis before bone marrow transplantation, and one who just completed mantle irradiation. Three patients died from this preparatory regimen, one of progressive interstitial pneumonitis, one of Legionella pneumonia, and one of multiorgan failure. Three patients with non-Hodgkin's lymphoma relapsed. Fourteen patients are currently alive and disease free to date. The actuarial are currently alive and disease free to date. The actuarial disease free survival was 57%, with a median follow-up of 23 months (range, 1-48 months).
  
  
  CONCLUSIONS
  The preparatory regimen consisting of lomustine/etoposide/cyclophosphamide is active in treating patients with lymphomas. Further trials with high doses of lomustine are warranted.
authors.affiliation: Bone Marrow Transplantation Program, Stanford University, California.
authors.forename: N J
authors.initials: NJ
authors.lastname: Chao
authors.forename: H
authors.initials: H
authors.lastname: Kastrissios
authors.forename: G D
authors.initials: GD
authors.lastname: Long
authors.forename: R S
authors.initials: RS
authors.lastname: Negrin
authors.forename: S J
authors.initials: SJ
authors.lastname: Horning
authors.forename: R M
authors.initials: RM
authors.lastname: Wong
authors.forename: T F
authors.initials: TF
authors.lastname: Blaschke
authors.forename: K G
authors.initials: KG
authors.lastname: Blume
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy*; D008875:Middle Aged; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D008130:Lomustine; D003520:Cyclophosphamide